我国首个自主研发的mRNA疫苗10月进入量产 年产能2亿剂
中国首个针对COVID-19的mRNA疫苗生产基地，
采用国产核心原材料和设备，
预计10月份投入使用。
专家表示，这证明
中国掌握了核心mRNA疫苗技术，将推动国家的大规模疫苗接种。
与军事医学科学院联合研制，
苏州阿博根和
云南华威生物科技有限公司
称为 ARCoVax 的 mRNA 疫苗
预计下个月将在中国西南云南省玉溪的基地投入量产。
With an investment of 520 million yuan ($80 million), the plant, China’s first production base for mRNA vaccine,
has the capacity to produce 200 million doses annually.
Compared with mRNA vaccines developed by the US and Germany,
the domestic mRNA vaccine is much safer as the selection of the vaccine antigen target is more precise and the neutralizing antibodies induced are higher,
media reports said.
The storage cost of this vaccine
is lower than those from overseas as it adopts a single injection in one package
and could be stored at room temperature for a week or at 4 C for a long time, making it easier to use.
A Beijing-based immunologist told the Global Times on Thursday that
the domestically produced mRNA vaccine demonstrates China’s huge improvements in mRNA technology and the country’s leading position in biotechnology.
ARCoVax has been approved to initiate its late-stage clinical trials in Mexico and Indonesia
by local health authorities, Yunnan Walvax Biotechnology Co announced on August 31.
Global Times
https://www.globaltimes.cn/page/202109/1233797.shtml
Mexico to start late-stage clinical trial for China’s mRNA COVID-19 vaccine
MEXICO CITY (Reuters)
Mexico plans to start a late-stage clinical trial this month for a COVID-19 vaccine candidate developed by China using similar technology to shots from Moderna and Pfizer,foreign minister Marcelo Ebrard said on Tuesday.
The phase III trial for the shot from China’s Walvax Biotechnology using messenger RNA (mRNA) technology will start on May 30 and involve 6,000 volunteers, Ebrard said in a Tweet.
https://ca.movies.yahoo.com/mexico-start-phase-iii-clinical-123058946.html